> Superbug and diabetic foot
Current topical antibiotics are ineffective against bacterial biofilm infections and have high propensity for development of resistance. TNP-2092 is multi-targeting drug conjugate specifically designed for the treatment of bacterial biofilm infections. TNP-2092 possesses a novel mechanism of action by inhibiting RNA polymerase, DNA gyrase and DNA topoisomerase IV, three essential targets for bacteria living in biofilms. TNP-2092 is highly potent against pathogens living in bacterial biofilms and pathogens resistant to available antibiotics with an extremely low propensity for development of resistance. A topical formulation of TNP-2092 is currently under preclinical development for the treatment superbug and diabetic foot infections.